Impact of hyponatremia on frequency of complications in patients with decompensated liver cirrhosis
Keywords:
liver cirrhosis, hyponatremia, ascites, hepatorenal syndrome, hepatic encephalopathyAbstract
Introduction: Hyponatremia is common in cirrhosis. The relationship between hyponatremia and severity of cirrhosis is evidenced by its close association with the occurrence of complications, the prevalence of hepatic encephalopathy, hepatorenal syndrome, spontaneous bacterial peritonitis, refectory ascites, and hepatic hydrothorax. The aim of this study was assess the impact of hyponatremia on the occurrence of both liver-related complications and the hemodynamic cardiovascular dysfunction.
Methods: This prospective study was conducted in 2015 on 74 patients with liver cirrhosis. The patients were from the Gastroenterology and Hepatology Department of Theodor Bilharz Research Institute in Giza, Egypt. The patients were divided into three groups according to their serum level of sodium. Group 1 included 30 patients with serum sodium >135 meq/L, group 2 included 24 patients with serum sodium between135 and 125 meq/L, and group 3 included 20 patients with serum sodium <125 meq/L. For each of the patients, we conducted aclinical examination, laboratory investigations, chest X-ray, ECG, abdominal sonar, and echocardiography.
Results: Hyponatremia was found in 59.46% of our cirrhotic patients, and they showed significantly increased Model for End-Stage Liver Disease (MELD) score, MELD-Na score, QTc interval, Pulmonary vascular resistance (PVR) and inferior vena cava (IVC) collapsibility, and decreased SVR and IVC diameter. Also hepatic encephalopathy, ascites, renal failure, infectious complications, and pleural effusion were significantly more common in hyponatremic cirrhotic patients.
Conclusion: In cirrhosis, hyponatremia is more common in severe cardiovascular dysfunction and associated with increased risk of hepatic encephalopathy, ascites, illness severity scores, renal failure, infectious complications, and pleural effusion. We recommend selective oral administration of vasopressin V2-receptor antagonist, tolvaptan, which acts to increase the excretion of free water, thereby resolving hypervolemic hyponatremia and may have the potential to improve outcomes in these patients.
References
Heidelbaugh JJ, Bruderly M. Cirrhosis and chronic liver failure: part I. Diagnosis and evaluation. Am Fam
Physician. 2006; 74(5):756–62. PMid: 16970019
Angeli P, Wong F, Watson H, Ginès P. Hyponatremia in cirrhosis:Results of a patient population survey.
Hepatology 2006; 44:1535-42. doi: 10.1002/hep.21412, PMid: 17133458
Piano S, Morando F, Angeli P. Hyponatremia and other electrolyte/ion disorders.Cirrhosis: A practical
guide to management, chapter 18, First Edition, John Wiley & Sons, Ltd. Published 2015.
Bernardi M, Ricci CS,Santi L. Hyponatremia in Patients with Cirrhosis of the Liver. J. Clin. Med. 2015, 4,
-101. doi: 10.3390/jcm4010085, PMid: 26237020, PMCid: PMC4470241
Iwakiri, Y.; Groszmann, R.J. The hyperdynamic circulation of chronic liver diseases: From the patient to
the molecule. Hepatology, 2006, 43 (1), 121–131. doi: 10.1002/hep.20993, PMid: 16447289
Martin, P.Y.; Ohara, M.; Ginès, P.; Xu, D.L.; St John, J.; Niederberger, M.; Schrier, R.W. Nitric oxide
synthase (NOS) inhibition for one week improves renal sodium and water excretion in cirrhotic rats with
ascites. J. Clin. Investig. 1998, 101, 235-42. doi: 10.1172/JCI626, PMid: 9421486, PMCid: PMC508560
Bichet, D.G. Posterior pituitary. In The Pituitary, 1st ed.; Melmed, S., Ed.; Blackwell Scientific
Publications, Inc.: Cambridge, MA, USA, 1995:277-306.
Esteva-Font, C.; Baccaro, M.E.; Fernández-Llama, P.; Sans, L.; Guevara, M.; Ars, E.; Jiménez, W.;
Arroyo, V.; Ballarín, J.A.; Ginès, P. Aquaporin-1 and aquaporin-2 urinary excretion in cirrhosis:
Relationship with ascites and hepatorenal syndrome. Hepatology, 2006, 44:1555–63. doi:
1002/hep.21414, PMid: 17133493
Pugh RN; Murray-Lyon I.M; Dawson JL; Pietroni MC; Williams R Transection of the oesophagus for
bleeding oesophageal varices. Br. J. Surg. 1973, 60:646-9. doi: 10.1002/bjs.1800600817, PMid: 4541913
Kim JH, Lee JS, Lee SH, et al. The association between the serum sodium level and the severity of
complications in liver cirrhosis. Korean J Intern Med. 2009;24:106–12. doi: 10.3904/kjim.2009.24.2.106,
PMid: 19543488, PMCid: PMC2698618
Londoño, M.C.; Cárdenas, A.; Guevara, M.; Quintó, L.; de Las Heras, D.; Navasa, M.; Rimola, A.; Garcia- Valdecasas, J.C.; Arroyo, V.; Ginès, P. MELD score and serum sodium in the prediction of survival of
patients with cirrhosis awaiting liver transplantation. Gut, 2007, 56:1283-90. doi:
1136/gut.2006.102764, PMCid: PMC1954951
Londoño, M.C.; Guevara, M.; Rimola, A.; Navasa, M.; Taurà, P.; Mas, A.; García-Valdecasas, J.C.;
Arroyo, V.; Ginès, P. Hyponatremia impairs early post-transplantation outcome in patients with cirrhosis
undergoing liver transplantation. Gastroenterology, 2006; 130:1135-43. doi: 10.1053/j.gastro.2006.02.017,
PMid: 16618408
Heuman DM, Abou-Assi SG, Habib A, Williams LM, Stravitz RT, Sanyal AJ, Fisher RA, Mihas AA.
Persistent ascites and low serumsodium identify patients with cirrhosis and low MELD scores who are at
high risk for early death. Hepatology, 2004; 40:802-10. doi: 10.1002/hep.1840400409, PMid: 15382176
John S and Thuluvath PJ. Hyponatremia in cirrhosis: Pathophysiology and management. World J
Gastroenterol, 2015 March 21; 21(11): 3197-205. PMID: 25805925 , PMCid: PMC4363748
Moller S, Henriksen JH. Cirrhotic cardiomyopathy. J Hepatol, 2010;53:179-90. doi:
1016/j.jhep.2010.02.023, PMid: 20462649
Lee RF, Glenn TK, Lee SS. Cardiac dysfunction in cirrhosis. Best Pract Res Clin Gastroenterol
;21:125-40. doi: 10.1016/j.bpg.2006.06.003
Gaskari SA, Honar H, Lee SS. Therapy insight: cirrhotic cardiomyopathy Nat Clin Pract Gastroenterol
Hepatol, 2006;3:329-37. doi: 10.1038/ncpgasthep0498
Kim MY, Baik SK, Won CS, Park HJ, Jeon HK, Hong HI, et al. Dobutamine stress echocardiography for
evaluating cirrhotic cardiomyopathy in liver cirrhosis. Korean J Hepatol, 2010;16:376–82. doi:
3350/kjhep.2010.16.4.376, PMID: 21415581, PMCid: PMC3304603
Finucci G, Desideri A, Sacerdoti D, et al. Left ventricular diastolic function in liver cirrhosis. Scand J
Gastroenterol1996;31:279-84. doi: 10.3109/00365529609004879
Wong F, Liu P, Lilly L, Bomzon A, Blendis L. Role of cardiac structural and functional abnormalities in
the pathogenesis of hyperdynamic circulation and renal sodium retention in cirrhosis. Clin Sci (Lond),
;97:259-67. doi: 10.1042/cs0970259
Beyer N, Aadahl M, Strange B, Kirkegaard P, Hansen BA, Mohr T, et al. Improved physical performance
after orthotopic liver transplantation. Liver Transpl Surg1999;5:301-9. doi: 10.1002/lt.500050406
Moller S, Wiinberg N, Hernriksen JH. Noninvasive 24-hour ambulatory arterial blood pressure monitoring
in cirrhosis. Hepatology, 1995;22:88-95.
Bernardi M, Calandra S, Colantoni A, et al. Q-T interval prolongation in cirrhosis: prevalence, relationship
with severity, and etiology of the disease and possible pathogenetic factors. Hepatology 1998;27:28-34.
doi: 10.1002/hep.510270106
Davenport A, Ahmad J, Al-Khafaji A, Kellum JA, Genyk YS, Nadim MK : Medical management of
hepatorenal syndrome. Nephrol Dial Transplant, 2012; 27:34–41, doi: 10.1093/ndt/gfr736
Ginès P, Guevara M, Arroyo V, Rodés J. Hepatorenal syndrome. Lancet, 2003; 362:1819-27, doi:
1016/S0140-6736(03)14903-3
Goldman MJ. Principles of clinical electrocardiography. 8th ed. Los Altos: Lage Medical, 1973:24
Gottdiener J.S., Bendnarz I., Devereaux R. et al. American Society of Echocardiography recommendations
for use of echocardiography in clinical trials. Journal of American Society of Echocardiography; 2004,
:1086-1119. doi: 10.1016/j.echo.2004.07.013
Teichholz LE, Kreulen T, Herman MV and Gorlin. Prblems in echocardiographic volume determinations.
Am J Cardiol. Jan 1976;37(1):7-11.
Lubien E, DeMaria A, Krishnaswamy P, Clopton P, Koon J et al. Utility of B Natriuretic Peptide in
Detecting Diastolic Dysfunction : Comparison With Doppler Velocity Recordings. Circulation,
;105:595-601. doi: 10.1161/hc0502.103010
Abbas AE, Noninvasive measurement of systemic vascular resistance using Doppler echocardiography J
Am Soc Echo, 2004;17(8):834-8, doi: 10.1016/j.echo.2013.06.003
Abbas AE, Franey LM, Marwick T, Maeder MT, Noninvasive Assessment of Pulmonary Vascular
Resistance by Doppler Echocardiography. J Am Soc Echocardiogr, 2013;26:1170-7.
Mandelbaum A and Ritz E Vena cava diameter measurement for estimation of dry weight in
haemodialysispatients Nephrol Dial Transplant, 1996; 11(2): 24-7, doi: 10.1093/ndt/11.supp2.24
Brennan JM, Blair JE, Goonewardena S, et al. Reappraisal of the use of inferior vena cava for estimating
right atrial pressure. J Am Soc Echocardiogr, 2007; 20:857-61. doi: 10.1016/j.echo.2007.01.005, PMid:
Feissel M, Michard F, Faller JP, Teboul JL. The respiratory variation in inferior vena cava diameter as a
guide to fluid therapy. Intensive Care Med, 2004; 30:1834–1837. doi: 10.1007/s00134-004-2233-5, PMid:
Weekes A, Tassone H, Babcock A, et al. Comparison of serial qualitative and quantitative assessments of
caval index and left ventricular systolic function during early fluid resuscitation of hypotensive emergency
department patients. Acad Emerg Med, 2011; 18:912-21. doi: 10.1111/j.1553-2712.2011.01157.x
Goldflam K, Saul T and Lewiss R, Focus On: Inferior Vena Cava Ultrasound. ACEP News, June 2011
Kim WR, Biggins SW, Kremers WK, et al. .Hyponatremia and mortality among patients on the livertransplant waiting list. N Engl J Med, 2008;359:1018-26. doi: 10.1056/NEJMoa0801209, PMid: 18768945,
PMCid: PMC4374557
Pugliese R, Fonseca EA, Porta G, et al. Ascites and serum sodium are markers of increased waiting list
mortality in children with chronic liver failure. Hepatology, 2013. Oct 7;Epub ahead
Samuel D. MELD-Na as a prognostic score for cirrhotic patients: Hyponatremia and ascites are back in the
game. J Hepatol. 2009;50(4):836-8. doi: 10.1016/j.jhep.2008.12.015, PMid: 19231009
Ruf AE, Kremers WK, Chavez LL, Descalzi VI, Podesta LG, Villamil FG. Addition of serum sodium into
the MELD score predicts waiting list mortality better than MELD alone. Liver Transpl. 2005;11(3): 336- 43. doi: 10.1002/lt.20329, PMid: 15719386
Zardi EM, Abbate A, Zardi DM, et al. Cirrhotic cardiomyopathy. J Am Coll Cardiol, 2010;56:539-49. doi:
1016/j.jacc.2009.12.075, PMid: 20688208
Møller S, Henriksen J. Cirrhotic cardiomyopathy: a pathophysiological review of circulatory dysfunction in
liver disease. Heart, 2002;87:9-15. doi: 10.1136/heart.87.1.9, PMid: 11751653, PMCid: PMC1766971
Moller S, Dumcke CW, Krag A. The heart and the liver. Expert Rev Gastroenterol Hepatol, 2009;3:51-64.
doi: 10.1586/17474124.3.1.51, PMid: 19210113
Gaduputi V, Abdulsamad M, Sakam S, Abbas N, Tariq H, and Ihimoyan A. Systemic vascular resistance in
cirrhosis: a predictor of severity? Hepat Med. 2014; 6: 95-101. PMid: 25187743, PMCid: PMC4128691
Goitein O, Matetzky S, Beinart R, et al., “Acute myocarditis: noninvasive evaluation with cardiac MRI and
transthoracic echocardiography,” American Journal of Roentgenology, 2009; 192(1):254-8, doi:
2214/AJR.08.1281, PMid: 19098207
Valeriano V, Funaro S, Lionetti R et al., “Modification of cardiac function in cirrhotic patients with and
without ascites,” American Journal of Gastroenterology, 2000;95(11):3200-5, doi: 10.1111/j.1572- 0241.2000.03252.x, PMid: 11095342
Garg A, William F. Armstrong. Echocardiography in Liver Transplant Candidates. J Am Coll Cardiol Img.
;6(1):105-19, doi: 10.1016/j.jcmg.2012.11.002
Pozzi M., Carugo S., Boari G., Evidence of functional and structural cardiac abnormalities in cirrhotic
patients with and without ascites. Hepatology. 1997;26:1131-7
Abd-El-Aziz T.A., Abdou M., Fathy A., Wafaie M.; Evaluation of Cardiac Function in Patients with
Liver Cirrhosis. Intern Med. 2010;49:2547-52. doi: 10.2169/internalmedicine.49.3520, PMid: 21139291
Venkateshwarlu N, Gandiah P, Indira G, Sivarajapp A and Prabhakar K. cardiac abnormalities in patients
with cirrhosis. Indian J.L.Sci. 2013;3(1):105-11
Mandell MS, Lindenfeld JA, Tsou MY, and Zimmerman M, “Cardiac evaluation of liver transplant
candidates,” World Journal of Gastroenterology, 2008; 4 (220):3445-51
Sun FR, Wang Y, Wang BY, Tong J, Zhang D, and Chang B, “Relationship between model for end-stage
liver disease score and left ventricular function in patients with end-stage liver disease,” Hepatobiliary and
Pancreatic Diseases International, 2011;10(1):50-4, doi: 10.1016/S1499-3872(11)60007-6
Moaref A, Zamirian M, Yazdani M, Salehi O, Sayadi M , Aghasadeghi K. The Correlation between
Echocardiographic Findings and QT Interval in Cirrhotic Patients. Int Cardiovasc Res J. 2014; 8(2): 39-43,
PMid: 24936479, PMCid: PMC4058482
Rudski LG, Lai WW, Afilalo J, et al. Guidelines for the echocardiographic assessment of the right heart in
adults: a report from the American Society of Echocardiography endorsed by the European Association of
Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of
Echocardiography. J Am Soc Echocardiogr, 2010; 23(7):685-713. doi: 10.1016/j.echo.2010.05.010, PMid:
Jenq CC, Tsai MH, Tian YC et al., “Serum sodium predicts prognosis in critically ill cirrhotic patients,” J.
Clin Gastroenterology, 2010; 44(3):220-6, doi: 10.1097/MCG.0b013e3181aabbcd, PMid: 19636261
Guevara, M.; Baccaro, M.E.; Torre, A.; Gomez-Anson, B.; Rios, J.; Torres, F.; Rami, L.; Monte-Tubio,
G.C.; Martin-Llahi, M.; Arroyo, V.; et al. Hyponatremia is a risk factor of hepatic encephalopathy in
patients with cirrhosis: A prospective study with time-dependent analysis. Am. J. Gastroenterol. 2009, 104,
-9. doi: 10.1038/ajg.2009.293, PMid: 19455124
Follo A, Llovet JM, Navasa M, et al. Renal impairment after spontaneous bacterial peritonitis in cirrhosis:
Incidence, clinical course, predictive factors and prognosis. Hepatology, 1994;20:1495-501. doi:
1002/hep.1840200619, PMid: 7982650
Sort P, Navasa M, Arroyo V, et al .Effect of intravenous albumin on renal impairment and mortality in
patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med, 1999;341:403-9. doi:
1056/NEJM199908053410603, PMid: 10432325
Priyank U, Vibha, C. and Vishwanath, H. L. The association between hyponatremia and severity of
complications in liver cirrhosis International Journal of Current Research, 2013; 5(9):2446-8
Hackworth WA, Heuman DM, Sanyal AJ, et al. Effect of hyponatraemia on outcomes following orthotopic
liver transplantation. Liver Int. 2009;29:1071-7. doi: 10.1111/j.1478-3231.2009.01982.x, PMid: 19302181
Weismüller TJ, Fikatas P, Schmidt J, et al. Multicentric evaluation of model for end-stage liver disease- based allocation and survival after liver transplantation in Germany-limitations of the ‘sickest first’
concept. Transpl Int. 2011;24:91-99. doi: 10.1111/j.1432-2277.2010.01161.x, PMid: 20819196
Figueiredo A, Romero-Bermejo F, Perdigoto R and Marcelino A. The End-Organ Impairment in Liver
Cirrhosis: Appointments for Critical Care. Critical Care Research and Practice, 2012, Article ID: 539412
Alberts WM, Salem AJ, Solomon DA, and Boyce G,“Hepatic hydrothorax: cause and management,”
Archives of Internal Medicine, 1991; 151(12):2383–8, doi: 10.1001/archinte.1991.00400120029005, PMid:
Lazaridis KN, Frank JW, Krowka MJ, and Kamath PS, “Hepatic hydrothorax: pathogenesis, diagnosis, and
management,” American Journal of Medicine, 1999; 107(3):262-7, doi: 10.1016/S0002-9343(99)00217-X
Zhang X, Wang SZ, Zheng JF, Zhao WM, Li P, Fan CL et al., Clinical efficacy of tolvaptan for treatment
of refractoryascites in liver cirrhosis patients. World J Gastroenterol, 2014, 28; 20(32): 11400-5.
Published
Issue
Section
License
Copyright (c) 2020 knowledge kingdom publishing
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
